Literature DB >> 11504162

Effects of mibefradil, a T- and L-type calcium channel blocker, on cardiac remodeling in the UM-X7.1 cardiomyopathic hamster.

J Villame1, J Massicotte, G Jasmin, L Dumont.   

Abstract

Abnormalities of T-type calcium channel function reported to occur in the transition phase to heart failure in the hamster cardiomyopathy may contribute to progression of the disease. We tested the hypothesis that chronic exposure to mibefradil, a selective T-type calcium channel blocker, improves the deleterious cardiac remodeling observed in this condition. In the present study, 40 normal (N) and 40 UM-X7.1 cardiomyopathic hamsters (CMH), aged 180 days, were treated daily by gavage for 21 days with mibefradil (30 mg/Kg). Eight to 10 animals from each group were sacrificed at the end of the treatment period while the remainder were followed for an additional 30 days without treatment (washout period). Hearts were harvested, fixed with 10%-buffered paraformaldehyde and then cut in half down the middle. Several slices were dehydrated, embedded in paraffin and stained with Masson Trichrome. Wall thickness and dilatation index of the left ventricle were estimated by planimetry. Myocardial capillary density was also computed. The greater heart weight/body weight ratio seen in untreated CMH (7.7 +/- 0.4 vs 5.5 +/- 0.2 in N, p < 0.05) was improved with mibefradil. The dilatation index averaged 0.504 +/- 0.04 in N was increased in untreated CMH (0.566 +/- 0.03) and ameliorated in mibefradil-treated CMH. The 1-month washout period led to further deterioration of the dilatation index in untreated and mibefradil-treated CMH. Capillary density averaged 10,000 +/- 781 per mm2 in hearts from untreated N hamsters and 8,830 +/- 795 per mm2 in untreated CMH (p = NS). Chronic exposure to mibefradil resulted in a significant reduction of capillary density in both N and CMH hearts. Following the 1-month washout period, the change in myocardial capillary density associated with mibefradil was no longer detectable. In conclusion, chronic exposure to mibefradil, a T- and L-type calcium channel blocker, exerts opposite effects during the transition phase to heart failure in CMH, improving the deleterious left ventricular remodeling in UM-X7.1 hamsters and reducting myocardial capillary density independently of the disease process.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504162     DOI: 10.1023/a:1011158717901

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  5 in total

Review 1.  Low-voltage-activated ("T-Type") calcium channels in review.

Authors:  Anne Marie R Yunker; Maureen W McEnery
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

2.  Mutation of delta-sarcoglycan is associated with Ca(2+) -dependent vascular remodeling in the Syrian hamster.

Authors:  Larissa Lipskaia; Caroline Pinet; Yves Fromes; Stéphane Hatem; Isabelle Cantaloube; Alain Coulombe; Anne-Marie Lompré
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

Review 3.  Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation.

Authors:  Narutaka Ohashi; Hideo Mitamura; Satoshi Ogawa
Journal:  Drugs       Date:  2009       Impact factor: 9.546

4.  New Generation Calcium Channel Blockers in Hypertensive Treatment.

Authors:  Yuri Ozawa; Koichi Hayashi; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006-05-01

5.  δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.

Authors:  Alison M Blain; Volker W Straub
Journal:  Skelet Muscle       Date:  2011-03-17       Impact factor: 4.912

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.